The expansion plan includes a 50,000ft² facility, which will allow PCI to expand its services as a global CDMO in biologics packaging and speciality manufacturing with a multi-product facility to cater to new and existing customers
US-based PCI Pharma Services (PCI) has announced an investment of $100m to expand the capacity of its Bedford campus in New Hampshire, US.
With the investment, the firm will boost the capacity of sterile lyophilization and liquid filling technology, a key manufacturing process used for injectable and biologic therapies.
The expansion plan includes a 50,000ft² facility, which will allow PCI to expand its services as a global CDMO in biologics packaging and speciality manufacturing with a multi-product facility to cater to new and existing customers.
The facility will be equipped with technology like an aseptic fill-finish line with a fully separated containment system.
It will also include twin lyophilizers with auto-loading and unloading equipment, capable of filling 400 vials per minute on a sterile fill-finish line.
Upon completion of the expansion, PCI will be able to meet the demand for integrated big and small molecule solutions for clinical and commercial clients.
PCI Pharma Services CEO Salim Haffar said: “We are excited to introduce clients to our newest facility, which is part of our broader strategy to provide integrated end-to-end drug development, manufacturing and packaging capabilities.
“Our investment in these facilities will ensure that PCI continues to leverage new capabilities in complex formulations, aseptic fill-finish, and lyophilization to meet the needs of our global clients, particularly as biologics continue their strong growth trajectory.”
The expansion is the latest in a string of global expansions spanning several continents and five more locations, including Berlin; San Diego; Rockford, Illinois; and Melbourne, Australia.
The expanded Bedford plant will specialise in high-volume lyophilization, liquid filling, and multi-format product handling.
PCI said it will also expand three more Bedford-based facilities with additional aseptic fill-finish and lyophilization capabilities to meet market and dedicated customer requirements.
In December last year, PCI closed the acquisition of Lyophilization Services of New England, a contract development and manufacturing firm based in Bedford, New Hampshire.